Below is a reception from Sanofi-Aventis regarding an artefact that appeared in The Lancet arch about Acomplia (Rimonabant)׃
"The meta-analyses published mean solar day in the Lance and BMJ reflect the data previously published, and do not introduce any new accusal that doctors, sanofi-aventis and regulatory bodies have not already considered and acted upon. The articles summarise the recognised benefits of Acomplia on metric and multiple risk factors, including glycaemic dominance in those with diabetes.
The authors also reputation the well established side result life story, including the psychiatric events that are already appreciated by clinicians who prescribe the event.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment